A new point of view on the potential role of epigenetic aberrations in cancer
Team leader, Céline Vallot, hopes to grasp the dynamics of epigenetic deregulations during in vitro and in vivo tumor progression using an innovative cell model to capture epigenetic alterations in real time. The project will focus on breast cancer.
Her project is at the crossroads of several disciplines: questions of fundamental as well as translational biology are asked based on integrated bioinformatics and biostatistical analyses.
Main research programs
- Characterizing the dynamics of acquisition of epigenetic alterations during tumorigenesis
- Evaluating the stability and phenotypic consequences of these alterations
- Model the mode of action of epigenetic treatments and discover new compounds acting on the tumor epigenome
Céline Vallot, PhD, PI
- Adeline Durand, engineer
- Justine Marsolier, PhD, post-doctorant
Vallot C*, Patrat C, Huret C, Collier A, Casanova M, Liyakat Ali T, Tosolini M, Heard E, Rugg-Gunn P, Rougeulle C*. XACT Noncoding RNA Competes with XIST in the Control of X Chromosome Activity during Human Early Development, Cell Stem Cell (2017), 20:102–111
Vallot C*, Ouimette JF*, Makhlouf M, Féraud O, Pontis J, Côme J, Martinat C, Bennaceur-Griscelli A, Lalande M, Rougeulle C. Erosion of X chromosome inactivation in human pluripotent cells initiates with XACT coating and depends on a specific heterochromatin landscape, Cell Stem Cell (2015), 16(5):533-46
Vallot C*, Herault A*, Boyle S, Bickmore WA, Radvanyi F§. PRC2-independent chromatin compaction and transcriptional repression in cancer, Oncogene (2015), 34(6):741-51
Vallot C, Huret C, Lesecque Y, Resch A, Oudrhiri N, Bennaceur-Griselli, Duret L, Rougeulle C. XACT, a long non-coding transcript coating the active X chromosome in human pluripotent cells, Nat Genet. (2013), 45(3):239-41
- Vallot C, Stransky N, Bernard-Pierrot I, Hérault A, Zucman-Rossi J, Chapeaublanc E, Vordos D, Laplanche A, Benhamou S, Lebret T, Southgate J, Allory Y, Radvanyi F. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst. (2011)